The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals

In Vivo

Volumn 21, Issue 1, 2007, Pages 1-16

  Prasanphanich, Adam F ^a,b   Lane, Stephanie R ^c   Figueroa, Said D ^a   Ma, Lixin ^a,b   Rold, Tammy L ^a,b   Sieckman, Gary L ^b   Hoffman, Timothy J ^a,b   McCrate, Joseph M ^a   Smith, Charles J ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

2,3 diaminopropionic acid; Bombesin; CT; Diagnostic radiopharmaceuticals; Gastrin releasing peptide; MRI; PC 3; Pharmacokinetics; Receptor; Site directed; Spacer; SPECT; Tc 99m; Tethering moiety

Indexed keywords

BOMBESIN TC 99M; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; METALLATION; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PROSTATE CANCER; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID PHASE SYNTHESIS; TUMOR XENOGRAFT;

EID: 33847637674     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. 64Cu-labeled bombesin analogue. Bioconjug Chem 14: 756-763, 2003.
2. Boerman OC, Oyen WJG and Corstens FHM: Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. Sem Nucl Med 30: 195-208, 2000.
3. Giblin MF, Wang N, Hoffman TJ, Jurisson SS and Quinn TP: Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci USA 95: 12814-12818, 1998.
4. 64Cu-labeled somatostatin analogues in vitro and in a tumor bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 42: 1341-1347, 1999.
5. 99mTc-Labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 99: 2235-2268, 1999.
6. Cutler CS, Smith CJ, Ehrhardt GJ, Tyler TT, Jurisson SS and Deutsch E: Current and potential therapeutic uses of Lanthanide radioisotopes. Cancer Biother Radiopharm 15(6): 531-545, 2000.
7. Smith CJ, Volkert WA and Hoffman TJ: Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 32(7): 733-740, 2005.
8. Giblin MF, Veerendra B and Smith CJ: Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer in vivo. New Anticancer Agents: In Vitro and In Vivo Evaluation 19: 9-30, 2005.
9. Smith CJ, Volkert WA and Hoffman TJ: Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol 30: 861-868, 2003.
10. 2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res 23: 63-70, 2003.
11. Eary JF, Schroff RW, Abrams PG, Fritzberg AR, Morgan AC, Kasina S, Reno JM, Srinivasan A, Woodhouse CS and Wilbur DS: Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies. J Nucl Med 30: 25-32, 1989.
12. Fritzberg AR and Wilbur DS: Radiolabeling of antibodies for targeted diagnostics. In: Targeted Delivery of Imaging Agents. Boca Raton, FL, CRC Press, Inc., pp. 83-101, 1995.
13. Goldenberg DM and Larson SM: Radioimmunodetection in cancer identification. J Nucl Med 33: 803-814, 1992.
14. Press OW, Appelbaum FR, Early JF and Bernstein ID: Radiolabeled antibody therapy of lymphomas. Biolog Ther of Cancer Update 4: 1-13, 1994.
15. Jain RK: Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81: 570-576, 1989.
16. 3. Cancer Res 63: 4082-4088, 2003.
17. 2: an in vitro/in vivo structure-activity relationship study where X = 0, 3, 5, 8, and 11-carbon tethering moteties. Bioconj Chem 14: 93-102, 2003.
18. 2: radiochemical evaluation with co-ligands EDDA(EDDA = ethylenediamine-N, N′-diacetic acid), tricine, and nicotinic acid. Synthesis and Reactivity in Inorganic, Metal-Organic and Nano-Metal Chemistry 35: 43-51, 2005.
19. 2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nuclear Medicine & Biology 30(2): 101-109, 2003.
20. 99mTc-labeled peptides. Q J Nucl Med 46: 195-205, 2002.
21. 3]+ moiety. Nuclear Medicine & Biology 33: 625-634, 2006.
22. 64Cu-labeled somatostatin analogues in vitro and in a tumorbearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 42: 1341-1347, 1999.
23. Stolz B, Smith-Jones PM, Weckbecker G, Albert R, Knecht H, Haller R, Tolcsvai L, Hofman G, Pollehn K and Bruns C: Radiotherapy with yttrium-90 labeled DOTATyr3- octreotide in tumor bearing rodents. J Nucl Med 38: 18p, 1997.
24. Anderson CJ and Welch MJ: Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev 99: 2219-2234, 1999.
25. 99mTc-labelled peptide-based radiopharmaceuticals: an overview. Nuclear Medicine Communications 20: 1093-1112, 1999.
26. Jurisson S, Berning D, Jia W and Ma D: Coordination compounds in nuclear medicine. Chem Rev 93: 1137-1156, 1993.
27. 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles and coligands. Bioconj Chem 9: 583-595, 1998.
28. 99mTc-labeling of highly potent small peptides. Bioconj Chem 8: 621-636, 1997.
29. Zalutsky MR and Narula AS: Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl) benzoate intermediate. Cancer Res 48: 1446-1450, 1988.
30. +. In: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine. Nicolini M, and Ulderico M (eds.), SGE, Italy, 1999, pp27-34.
31. + (M = Re, Tc) Directed Towards Radiopharmaceutical Application. Coord Chem Rev, pp. 190-192, 901-919, 1999.
32. 99mTc] Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med 30(2): 247-258, 2003.
33. 99mTc: a preclinical study. J Med Chem 48(1): 100-110, 2005.
34. Jurisson S and Lydon JD: Potential technetium small molecule radiopharmaceuticals. Chem Rev 99: 2205-2218, 1999.
35. Volkert WA and Hoffman TJ: Therapeutic radiopharmaceuticals. Chem Rev 99: 2269-2292, 1999.
36. Zalutsky MR and Bigner DD: Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol 35: 373-379, 1996.
37. 6] by Alkaline Titration. J Chem Soc Dalton Trans, pp. 2815-2820, 1994.
38. 177Lu-AMBA, a DOTA conjugate that targets GRP and NMB receptor expressing tumors: Internalization, in vivo biodistribution, single dose radiotherapy in PC-3 tumor-bearing nude mice and in vitro autoradiograpy in animal and human tissues. Euro Assoc Nucl Med, Helsinki, Finland, 2004.
39. 177Lu-AMBA; a radiotherapeutic compound that targets gastrin releasing peptide receptors. Euro Assoc Nucl Med, Helsinki, Finland, 2004.
40. 177Lu-DOTA conjugate for targeting of tumors expressing gastrin releasing peptide receptors (GRP-R). J Nuc Med 45(5): 169P, Abstract 482, 2004.
41. Mantey SA, Weber HC, Sainz E, Akeson M, Ryan RR, Pradhan TK, Searles RP, Spindel ER, Battey JF, Coy DH and Jensen RT: Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem 1272: 26062-26071, 1997.
42. Pradhan TK, Katsuno T, Taylor JE, Kim SH, Ryan RR, Mantey SA, Donohue PJ, Weber HC, Sainz E, Battey JF, Coy DH and Jensen RT: Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharm 343: 275-287, 1998.
43. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC and Maecke HR: Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 64: 6707-6715, 2004.
44. Fleischmann A, Laderach U, Friess H, Buechler MW and Reubi JC: Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Laboratory Investigation 80(12): 1807-1817, 2000.
45. Sano H, Feighner SD, Hreniuk DL, Iwaasa H, Sailer AW, Pan J, Reitman ML, Kanatani A, Howard AD and Tan CP: Characterization of the bombesin-like peptide receptor family in primates. Genomics 84: 139-146, 2004.
46. Van De Wiele C, Dumont F, Van Belle S, Slegers G, Peers SH and Dierckx RA: Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumor imaging? Nucl Med Comm 22: 5-15, 2001.